Search clinical trials for: Original Zoledronic Acid

Total 24016 results

Wales Cancer Trials Unit
Velindre NHS Trust

Unknown

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

Breast Cancer | Metastatic Cancer | Hypercalcemia of Malignancy

United Kingdom
Cttq

Unknown

Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women

Osteoporosis, Postmenopausal
Hospital Authority, Hong Kong
Baxter Healthcare Corporation

Completed

Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Prostatic Neoplasms | Bone Density

China
Duke University
Novartis; National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma

Osteoporosis | Brain Tumors | Central Nervous System(CNS)Malignancies

United States
University of Wisconsin, Madison
Novartis Pharmaceuticals

Completed

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

Prostate Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis

Bone Metastatic Non-small Cell Lung Cancer

China
University of Calgary

Recruiting

Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury (ZAPOA)

Osteo Arthritis Knee | Anterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament Tear

Canada
Yonsei University

Recruiting

A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis (ZOOM Study)

Osteoporosis

Korea, Republic of
Novartis Pharmaceuticals

Completed

The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss

Breast Cancer

Germany
Thomas J. Schnitzer
Novartis

Terminated

Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss

Bone Loss

United States
University of Calgary

Recruiting

Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation

Osteoporosis | Bone Loss | Osteopenia | Osteoporosis, Postmenopausal

Canada
Columbia University
Novartis Pharmaceuticals

Completed

Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation (CTX)

Liver Transplantation | Heart Transplantation | Bone Resorption

United States
Toufiqe-E-Ealahi

Recruiting

Effect of Zoledronic Acid in Primary Knee Osteoarthritis

Primary Osteoarthritis

Bangladesh
Children's Hospital of Eastern Ontario

Withdrawn

Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study

Acute Lymphoblastic Leukemia | Osteoporosis | Osteonecrosis

Canada
Stanford University
National Institutes of Health (NIH)

Withdrawn

Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients

Bone Marrow Transplant | Hematopoietic Stem Cell Transplant
Novartis Pharmaceuticals

Completed

Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid (LISA)

Osteoporosis

Australia
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

Breast Cancer | Osteoporosis

United States
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates

Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated
Novartis Pharmaceuticals

Completed

Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid

Osteoporosis

United States, Germany
Novartis

Terminated

Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions

Breast Cancer With Bone Metastasis

Germany
Novartis Pharmaceuticals

Completed

Non-small Cell Lung Cancer Registry

Pleural Effusion, Malignant | Non-Small-Cell Lung Cancer

United States
Novartis Pharmaceuticals

Completed

A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy

Prostate Cancer

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer (TRAPEZE)

Pain

France
Novartis Pharmaceuticals

Completed

Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

Cancer Prostate

Belgium
Novartis

Completed

Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases

Neoplasm Metastasis

Hungary
Novartis

Completed

Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer

Prostate Cancer

Germany
Instituto Mexicano del Seguro Social

Completed

Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma

Multiple Myeloma

Mexico
Stanford University
Novartis

Terminated

Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

Urologic Neoplasms

United States
Novartis Pharmaceuticals

Completed

1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

Osteoporosis

Australia, Canada, Russian Federation, Hungary, South Africa, United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Pain | Urinary Complications | Breast Adenocarcinoma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | Metastatic Malignant Neoplasm to the Bone | Musculoskeletal Complication

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

Prostate Cancer

United States
Novartis Pharmaceuticals

Completed

A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years

Postmenopausal Osteoporosis

Turkey
Novartis Pharmaceuticals

Completed

Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases

Prostate Cancer
Turku University Hospital
Novartis; Academy of Finland; Stryker Nordic

Completed

Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis

Hip Osteoarthritis

Finland
Novartis Pharmaceuticals

Completed

Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis

Neoplasm Metastasis | Renal Cell Cancer

Germany
Cancer Institute and Hospital, Chinese Academy...
Beijing Municipal Science & Technology Commission

Active, not recruiting

Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer

Triple Negative Breast Cancer
Novartis
Società Italiana di Urologia (SIU)

Completed

Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

Prostate Cancer

Italy
Novartis

Withdrawn

Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.

Multiple Myeloma
Universitaire Ziekenhuizen KU Leuven

Completed

A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)

Myelofibrosis | Myeloid Metaplasia

Belgium, Australia, France, Germany, Israel, Spain
Novartis Pharmaceuticals

Terminated

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

Prostate Cancer

United States
Novartis

Completed

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

Breast Cancer | Multiple Myeloma | Prostate Cancer

United States
Novartis

Terminated

Maintaining Bone Strength in Men With Prostate Cancer

Prostate Cancer

United Kingdom
Novartis

Completed

Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma

Treatment of Bone Metastases

China
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
University of Louisville
Novartis Pharmaceuticals; James Graham Brown Cancer Center

Terminated

Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

Carcinoma, Non-Small Cell Lung | Metastases | Carcinoma, Small Cell Lung

United States
University of Alabama at Birmingham
Novartis Pharmaceuticals

Completed

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) (UAB0901)

Mesothelioma

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy

Prostate Cancer

Venezuela
Thar Pharmaceuticals, Inc

Completed

Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women

Healthy Postmenopausal Women

United States
Peter Bushunow MD
Novartis Pharmaceuticals

Terminated

Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer (ZAP)

Non Small Cell Lung Cancer | Malignant Pleural Effusion

United States
Novartis Pharmaceuticals

Completed

A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate

Osteoporosis

United States

3

Subscribe